Мақола

Donor and stem cell source selection in hematopoietic cell transplantation in the Asia-Pacific region: results from the APBMT Activity Survey 2022-2023.

Minako IidaDepartment of Promotion for Blood and Marrow Transplantation, Aichi Medical University School of Medicine, Nagakute, JapanXiao Jun HuangDepartment of Hematology, Peking University Institute of Hematology, Beijing, ChinaMeng LvDepartment of Hematology, Peking University Institute of Hematology, Beijing, ChinaKaiyan LiuDepartment of Hematology, Peking University Institute of Hematology, Beijing, ChinaYachiyo KuwatsukaDepartment of Advanced Medicine, Nagoya University Hospital, Nagoya, JapanYoon Seok ChoiDepartment of Hematology, Catholic Hematology Hospital, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of KoreaHee-Je KimCatholic University of KoreaSeong-Kyu ParkDepartment of Hematology-Oncology, Soonchunhyang University Bucheon Hospital, Bucheon, Republic of KoreaSadhana KannanDepartment of Clinical Biostatistics, ACTREC, Tata Memorial Centre, Mumbai, IndiaBor-Sheng KoDepartment of Internal Medicine, National Taiwan University Hospital, Taipei, TaiwanChi-Cheng LiCenter of Stem Cell & Precision Medicine, Hualien Tzu Chi Hospital, Hualien, TaiwanKim Wah HoDepartment of Hematology, Hospital Ampang, Ampang Selangor, MalaysiaGin Gin GanDepartment of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, MalaysiaSuradej HongengRamathibodi HospitalUsanarat AnurathapanDepartment of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, ThailandAloysius HoDepartment of Hematology, Singapore General Hospital, SingaporeM. L. PoonDepartment of Hematology Oncology, National University Hospital Singapore, SingaporeTasneem FarzanaDepartment of Clinical Hematology, National Institute of Blood Disease and Bone Marrow Transplantation, Karachi, PakistanShafaq SamadDepartment of Clinical Hematology, National Institute of Blood Disease and Bone Marrow Transplantation, Karachi, PakistanJoycelyn SimDepartment of Medicine, Queen Mary Hospital, Hong KongGarret Leung Man KitDepartment of Medicine, Queen Mary Hospital, Hong KongPhu Chi DungStem Cell Transplantation Department, Blood Transfusion and Hematology Hospital, Ho Chi Minh, VietnamVo Thi Thanh BinhStem Cell Transplantation Department, National Institute of Hematology and Blood Transfusion, Hanoi, VietnamMafruha AkterDepartment of Hematology and BMT, Dhaka Medical College and Hospital, Dhaka, BangladeshLallindra GooneratneBone Marrow Transplant Unit, Nawaloka Hospital PLC, Colombo, Sri LankaMarjorie Rose BravoSt. Luke's Medical Center, Quezon City, IM Hematology/Blood and Marrow Transplant, Quezon, PhilippinesTeresita DumagayDepartment of Medicine, National Kidney and Transplant Institute, Quezon, PhilippinesAye Aye GyiDepartment of Clinical Hematology, North Okkalapa General Hospital, Yangon, MyanmarDamai SantosaDivision of Hematology Medical Oncology, Department of Internal Medicine, Dr. Kariadi Hospital/Diponegoro University, Semarang, IndonesiaDesta ArdiniDivision of Hematology Medical Oncology, Department of Internal Medicine, Dr. Kariadi Hospital/Diponegoro University, Semarang, IndonesiaBishesh Sharma PoudyalCivil Service Hospital, Clinical Hematology and Bone Marrow Transplant Unit, Kathmandu, NepalKhishigjargal BatsukhBone and Marrow Transplantation Team, Hematology Department, National First Central Hospital of Mongolia, Ulaanbaatar, MongoliaMikhail DrokovRepublican Specialized Scientific and Practical Medical Center of Hematology, Tashkent, UzbekistanTakanori TeshimaDepartment of Hematology, Hokkaido University Faculty of Medicine, Sapporo, JapanYoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation (JDCHCT), Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, JapanAlok SrivastavaDepartment of Clinical Haematology, St. John's Medical College Hospital, Bengaluru, IndiaNavin KhattryDepartment of Medical Oncology, ACTREC, Tata Memorial Centre, Mumbai, India

2026en

ABI

Аннотация

Background: Donor selection strategies for allogeneic hematopoietic cell transplantation (HCT) have evolved with the increasing use of haploidentical transplantation. However, contemporary patterns of donor and stem cell source selection according to disease category in the Asia-Pacific (AP) region remain insufficiently characterized. Methods: Aggregated data from the APBMT Activity Survey 2022-2023 were analyzed to evaluate donor type and stem cell source distributions for allogeneic HCT. Donors were categorized as HLA-identical sibling, haploidentical (including other related donors), or unrelated donor. Stem cell sources were classified as bone marrow (BM), peripheral blood (PB), cord blood (CB), or mixed graft sources. Malignant and non-malignant diseases were compared, and disease-specific analyses were performed for acute myeloid leukemia, myelodysplastic syndrome/myeloproliferative neoplasms, severe aplastic anemia, and hemoglobinopathy. Sensitivity analyses excluding data from China were conducted. Results: Donor selection differed between malignant and non-malignant diseases, with haploidentical donors accounting for approximately 45%-60% of allogeneic HCTs, followed by unrelated donors (20%-30%) and HLA-identical sibling donors (15%-25%). Regarding stem cell source, PB was the predominant source across disease categories, accounting for approximately 60%-70% of allogeneic HCTs. BM accounted for approximately 5%-17% of transplants, with somewhat higher use in non-malignant diseases. CB accounted for approximately 10%-12% of transplants in malignant diseases and 3%-4% in non-malignant diseases. These patterns were consistent in disease-specific analyses; however, exclusion of China resulted in a relative decrease in haploidentical transplantation and an increase in unrelated donor use, particularly in malignant diseases, as well as a marked reduction in mixed graft sources with a corresponding increase in bone marrow use. Despite these shifts, the overall predominance of peripheral blood as the stem cell source and the disease-specific trends were maintained. Conclusions: Across AP region, donor and stem cell source selection for allogeneic HCT demonstrates modest but consistent disease-specific differences, reflecting adaptation of transplantation strategies to disease context in contemporary clinical practice.

Ҳали таржима қилинмаган

Идентификаторлар

DOI: 10.31547/bct-2026-012

Иқтибослар ва манбалар

0 та иқтибос1 та фойдаланилган манба